liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
De novo design of a biologically active amyloid
VIB Switch Lab, Belgium; Katholieke University of Leuven, Belgium.
VIB Switch Lab, Belgium; Katholieke University of Leuven, Belgium.
VIB Switch Lab, Belgium; Katholieke University of Leuven, Belgium.
VIB Switch Lab, Belgium; Katholieke University of Leuven, Belgium.
Show others and affiliations
2016 (English)In: Science, ISSN 0036-8075, E-ISSN 1095-9203, Vol. 354, no 6313, 720-+ p.Article in journal (Refereed) Published
Abstract [en]

Most human proteins possess amyloidogenic segments, but only about 30 are associated with amyloid-associated pathologies, and it remains unclear what determines amyloid toxicity. We designed vascin, a synthetic amyloid peptide, based on an amyloidogenic fragment of vascular endothelial growth factor receptor 2 (VEGFR2), a protein that is not associated to amyloidosis. Vascin recapitulates key biophysical and biochemical characteristics of natural amyloids, penetrates cells, and seeds the aggregation of VEGFR2 through direct interaction. We found that amyloid toxicity is observed only in cells that both express VEGFR2 and are dependent on VEGFR2 activity for survival. Thus, amyloid toxicity here appears to be both protein-specific and conditional-determined by VEGFR2 loss of function in a biological context in which target protein function is essential.

Place, publisher, year, edition, pages
AMER ASSOC ADVANCEMENT SCIENCE , 2016. Vol. 354, no 6313, 720-+ p.
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
URN: urn:nbn:se:liu:diva-132985DOI: 10.1126/science.aah4949ISI: 000387326300028PubMedID: 27846578OAI: oai:DiVA.org:liu-132985DiVA: diva2:1054744
Note

Funding Agencies|European Research Council (ERC) under the European Union, ERC [647458]; VIB; Industrial Research Funds of KU Leuven (IOF); Funds for Scientific Research Flanders (FWO); Flanders Institute for Science and Technology (IWT); Federal Office for Scientific Affairs of Belgium (Belspo) [IUAP P7/16]; FWO; KU Leuven [PF/10/014]; Wellcome Trust Institutional Strategic Support Fund (ISSF) [015615/Z/14/Z]; Biotechnology and Biological Sciences Research Council through its Research Equipment Initiative scheme [BB/E012558/1]; Goran Gustafsson Foundation; Swedish Research Council; Swedish Alzheimer Foundation; Flemish government; AXA Research grant; Marie Sklodowska-Curie Individual Fellowship under the European Union [H2020-MSCA-IF-2014-ST]; KU Leuven Stem Cell Programme

Available from: 2016-12-09 Created: 2016-12-07 Last updated: 2016-12-09

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Nyström, SofieHammarström, PerNilsson, Peter
By organisation
ChemistryFaculty of Science & Engineering
In the same journal
Science
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 37 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf